Trial Profile
Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS ≥ 1.5)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Clofarabine (Primary) ; Amsacrine; Cytarabine; Idarubicin
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Registrational; Therapeutic Use
- 15 Dec 2023 This trial has been completed in the Netherlands (Global end date: 28 Sep 2023).
- 07 Jul 2012 Planned number of patients changed from 800 to 880, actual initiation date (25 Jan 2010) and additional trial location (Belgium) added as reported by European Clinical Trials Database.
- 07 Jul 2012 Status changed from planning to recruiting as reported by European Clinical Trials Database.